The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease.
Spanish researchers have used the induction of neuronal degeneration of intense light exposure in mice retina in an experimental model of retinitis pigmentosa.
Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables.
Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.
Stemedica Cell Technologies, Inc., (Stemedica),a manufacturer and developer of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium.
Stem cell technology for AMD treatment
Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.
A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky.
A new suite of optical coherence tomography (OCT) software applications for the Cirrus HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.
Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO).
The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences.
A genetic link between cats and humans for two forms of retinitis pigmentosa (RP) have been identified by a University of Missouri researcher.
Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc.
Researchers at the University of Sydney have reported findings that support evidence of an association between retinal microvascular signs and stroke.
Stem cells, extracted from bone marrow can restore damaged retinal tissue through new cell generation, according to a recent discovery by researchers at the University of Louisville.
Diets low in trans-unsaturated fat and rich in omega-3 fatty acids and olive oil may reduce the risk of AMD, according to a study by Chong et al., published in The Archives of Ophthalmology.
Sutureless transconjunctival 20 g ppv is, according to this study, an ideal technique for all vitreoretinal surgeries.
New research indicates that patients with diabetic retinopathy (DR) should also be screened for obstructive sleep apnoea (OSA).
A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health. The RetmarkerDR is able to calculate and provide important ratios regarding Microaneurysm Turnover (formation and disappearance rates) which are key indicators of progression of retinal diseases like Diabetic Retinopathy.
Speakers at the symposium "Retinal Surgery — New Dimensions in Patient Safety," described three methods/instruments to help surgeons minimize complications during surgery including improved endotamponade applications, new cannula designs and microscope data projections.
Retina navigation is a new retina therapy solution, four years in the making by OD-OS, which means a doctor can image, plan and treat using a single platform. It was demonstrated to over 100 doctors at the Euretina meeting.
The 9th Euretina Congress took place during May in Nice, France and was attended, according to the organisers, by around 1700 delegates. This was a seminal event and will be the last of its kind as next year it will join forces with ESCRS (European Society of Cataract and Refractive Surgeons) in Paris from 2–8 September.
A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health.
Central retinal vein occlusion (CRVO) is caused by obstruction of the central retinal vein that that leads to a back up of blood and fluid in the retina, resulting in retinal injury and loss of vision.
A new collaboration between Oxford BioMedica and Sanofi-Aventis is to develop and commercialise gene therapy treatments for retinal degenerative diseases such as Stargardt disease, the form of early-onset macular degeneration and Usher syndrome, a relatively rare genetic disease where sufferers are born deaf and lose vision within the first 10 years of life.
